Pakistan Drug Makers Vow Price Increases Lacking Import Costs Relief
This article was originally published in PharmAsia News
Pakistan's pharmaceutical industry is calling for relief from the government for the cost of raw materials they must import, threatening an increase in drug prices by as much as 20 percent
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.